TCBP

TC BioPharm (Holdings) PLC Sponsored ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cbiopharm.com
Employees(FY) 60
ISIN US87807D4007

Performance

-22.6%

1W

-29.81%

1M

+3.67%

3M

-85.51%

6M

-64.35%

YTD

-92.46%

1Y

Profile

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Advanced Technical Analysis

Technical Analysis of TCBP 2024-05-10

Overview:

In the last 5 trading days, TCBP stock has shown a downward trend in both price and volume. The moving averages (MA) have been declining, indicating a bearish trend. Momentum indicators like RSI and Stochastic Oscillator are also showing oversold conditions. Volatility has been decreasing, and volume indicators are also on a downward t...

See more ...

Recent News & Updates

2024-05-06 01:01
TC BioPharm Announces Exercise of Warrants for 3.1 Million Gross Proceeds(Prnewswire)
2024-05-05 23:32
ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range?(Investorplace)
2024-05-05 23:07
Warren Buffett Just Gave Up on Paramount (PARA) Stock(Investorplace)
2024-05-05 22:37
Why Is TC Biopharm (TCBP) Stock Up 51% Today?(Investorplace)
2024-05-05 20:30
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies(Prnewswire)
2024-04-03 22:37
Why Is TC Biopharm (TCBP) Stock Up 78% Today?(Investorplace)
2024-04-03 20:32
TCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies(Prnewswire)
2024-04-01 20:30
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process(Prnewswire)
2024-03-18 20:30
TCBP Adjourns General Meeting Until a Later Date(Prnewswire)
2024-03-17 20:30
TCBP Announces Exercise of Series D Warrants For Cash(Prnewswire)
2024-02-29 19:30
Bryan Kobel, CEO of TCBP, Appears on Nationally Syndicated 'The Big Biz Show'(Prnewswire)
2024-02-26 19:30
TCBP Announces Shareholder Update Call on March 5th 2024(Yahoo Finance)
2024-02-21 20:32
TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial(Prnewswire)
2024-02-14 19:30
TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe(Prnewswire)
2024-02-13 19:30
TCBP Provides Shareholder Update and Highlights Upcoming Milestones(Yahoo Finance)
2024-01-28 19:30
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'(Prnewswire)
2024-01-17 19:30
TC BioPharm to Present at the Sequire Investor Summit(Prnewswire)
2024-01-03 19:30
TC BioPharm Regains Compliance with Nasdaq Minimum Bid Price Requirement(Prnewswire)
2024-01-02 19:30
TC BioPharm Announces Additional Cost Reduction Steps to Improve Financial Standing and Streamline Efficiencies(Prnewswire)
2023-12-21 19:30
TC BioPharm Announces Closing of $3.5 Million Public Offering(Prnewswire)
2023-12-18 19:00
TC BioPharm Announces Pricing of $3.5 Million Public Offering(Prnewswire)
2023-12-17 22:15
TC BioPharm Announces Formation of Commercial Development Division, Led by Industry Veteran, Dr. Lauren Bor Ph.D(Prnewswire)
2023-12-12 17:30
TC BioPharm Announces Plan to Implement ADS Ratio Change(Prnewswire)
2023-11-27 22:05
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug(Yahoo Finance)
2023-11-26 19:45
TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia(Prnewswire)
2023-11-13 21:00
TC BioPharm Announces Successful Completion of Safety Cohort and Positive DSMB Results(Prnewswire)
2023-11-02 01:30
TC BioPharm Announces Streamlined Efficiencies and Reduces Overhead with Selection of Single Global CRO for Clinical Trials(Prnewswire)
2023-10-24 20:00
TC BioPharm Selects Excellos as CDMO in Anticipation of Expanded US Clinical Trial Requirements(Prnewswire)
2023-10-23 20:45
Why the Relapsed/Refractory Acute Myeloid Leukemia Market is Expected to Witness Revolutionary Developments(Prnewswire)
2023-10-22 20:00
TC BioPharm Announces Submission of Investigational New Drug (IND) Application to U.S. FDA for Treatment of Relapse/Refractory AML(Yahoo Finance)

Page 1 of 3

previousnext